Pathstone Family Office’s Ionis Pharmaceuticals IONS Stock Holding History

Pathstone Family Office’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-477	Closed	-$27K	–	989
2020 Q4	$27K	Buy	477 +302	+173%	+$15.1K	﹤0.01%	627
2020 Q3	$9K	Hold	175	–	–	﹤0.01%	616
2020 Q2	$11K	Sell	175 -107	-38%	-$5.95K	﹤0.01%	502
2020 Q1	$14K	Buy	+282	New	+$15.7K	﹤0.01%	467
2019 Q2	–	Sell	-146	Closed	-$12K	–	760
2019 Q1	$12K	Hold	146	–	–	﹤0.01%	489
2018 Q4	$8K	Buy	+146	New	+$7.45K	﹤0.01%	347

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Pathstone Family Office's IONS Position: Q1 2021 in Review

Pathstone Family Office sold out of Ionis Pharmaceuticals (IONS) in Q1 2021, closing a stake of 477 shares — an estimated $27K sold.

Pathstone Family Office first reported a position in IONS in Q4 2018 and held it in 6 quarters. The position peaked at $27K in Q4 2020. 364 funds tracked by Wall St. Rank hold IONS as of Q1 2021.

Pathstone Family Office reported no remaining Ionis Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Pathstone Family Office sold 477 Ionis Pharmaceuticals shares in Q1 2021, an estimated $27K.
Pathstone Family Office first reported a position in Ionis Pharmaceuticals in Q4 2018 and held it in 6 quarters.
Pathstone Family Office's Ionis Pharmaceuticals position peaked at $27K in Q4 2020.
364 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2021.

Based on Pathstone Family Office's 13F filing for Q1 2021, filed 14 May 2021.